Skip to main content

Table 7 Effects of clinical parameters on the relationship between NLR and poor recovery

From: Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study

Variables

N

Poor Recovery

OR (95% CI)

P value

P for interaction

Age, years

 < 60

261

1.33 (1.19–1.49)

< 0.001

0.774

 ≥60

63

1.28 (1.10–1.63)

0.048

Sex

 Male

93

1.26 (1.09–1.47)

0.003

0.520

 Female

231

1.43 (1.23–1.67)

< 0.001

Hypertension

 No

279

1.33 (1.19–1.49)

< 0.001

0.701

 Yes

45

1.27 (1.02–1.57)

0.031

Initial EDSS

 < 6

206

1.38 (1.19–1.61)

< 0.001

0.188

 ≥6

118

1.21 (1.07–1.37)

< 0.003

Anti-AQP4 antibodies

 Negative

91

1.34 (1.10–1.63)

0.004

0.819

 Positive

180

1.38 (1.19–1.60)

< 0.001

LETM

 No

55

1.20 (0.96–1.50)

0.114

0.705

 Yes

165

1.26 (1.12–1.42)

< 0.001

Immunoglobulins

 No

291

1.31 (1.18–1.45)

< 0.001

0.573

 Yes

33

1.46 (0.99–2.15)

0.057

Immunosuppressants

 No

213

1.28(1.15–1.43)

< 0.001

0.274

 Yes

111

1.46 (0.99–2.15)

< 0.001

PLR

 < 190

234

1.44 (1.18–1.76)

< 0.001

0.090

 ≥190

90

1.18 (1.05–1.33)

< 0.001

LMR

 < 2.85

96

1.28 (1.09–1.52)

0.003

0.728

 ≥2.85

228

1.24 (1.09–1.40)

< 0.001

DMT

 NO

279

1.32 (1.18–1.48)

< 0.001

0.312

 YES

45

1.18(1.00–1.39)

0.051

  1. Diabetes and hormones are too different between the groups, and the interaction is negligible
  2. EDSS Extended disability status scale, LMR Lymphocyte-to-monocyte technical ratio, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, LETM longitudinally extensive transverse myelitis, AQP4 aquaporin-4, DMT disease-modifying treatment started during the follow-up